8-BROMO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL HYDROBROMIDE
| 中文名稱 | 8-BROMO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL HYDROBROMIDE |
|---|---|
| 中文同義詞 | 化合物SKF-83566;8-溴-3-甲基-5-苯基-2,3,4,5-四氫-1H-苯并[D]氮雜卓-7-醇;8-BROMO-2,3,4,5-四氫-3-甲基-5-苯基-1H-3-苯并嗪-7-OL;化合物SKF-83566,10 MM DMSO 溶液 |
| 英文名稱 | 8-BROMO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL HYDROBROMIDE |
| 英文同義詞 | SKF 83566 HYDROBROMIDE;8-BROMO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL HYDROBROMIDE;(+/-)-SKF-83566 HYDROCHLORIDE SELECTIVE DOPAMINE D1;(±)-SCH-24543, (±)-7-Bromo-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride;1H-3-Benzazepin-7-ol, 8-broMo-2,3,4,5-tetrahydro-3-Methyl-5-phenyl-;8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol;159021;SKF 83566 hydrobromi |
| CAS號(hào) | 99295-33-7 |
| 分子式 | C17H18BrNO |
| 分子量 | 332.23 |
| EINECS號(hào) | 604-604-1 |
| 相關(guān)類別 | Dopamine receptor |
| Mol文件 | 99295-33-7.mol |
| 結(jié)構(gòu)式 |  |
8-BROMO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL HYDROBROMIDE 性質(zhì)
| 儲(chǔ)存條件 | Desiccate at RT |
|---|---|
| 溶解度 | 45%(w/v)aq2-羥丙基-β-環(huán)糊精：≥14 mg/mL |
| 形態(tài) | 固體 |
| 顏色 | 駝色 |
|
D 1 Receptor
|
D 5 Receptor
|
5-HT 2 Receptor 11 nM (Ki) |
SKF-83566 (0.1 μM-10 μM) causes a concentration-dependent increase in peak evoked extracellular DA concentration ([DA] o )?evoked by single-pulse stimulation, with a maximum 65% increase in peak evoked [DA] o with 5 μM. The EC 50 value of this effect of SKF-83566 is 1.3 μM.SKF-83566 inhibited [ 3 H]DA uptake with an IC 50 of 5.73 μM. Moreover, SKF-83566 more potently inhibits the binding of [ 3 H]CFT, a cocaine analog, with an IC 50 of 0.51 μM in [ 3 H]DA uptake and [ 3 H]CFT binding studies.Similarly, in LLc-PK-rDAT cell, SKF-83566 also inhibits [ 3 H]CFT binding with an IC 50 of 0.77 μM in LLc-PK-rDAT cell membrane preparations.
SKF 83566 hydrobromide (oral administration; 20 μg/mL; 7 days) alone has no effects on altering LTP (115%). However, combinnation of SKF 83566 and nicotine significantly blocks the enhancement of long-term synaptic potentiation (LTP) induced by pretreatment with nicotine (SKF 83566+nicotine+cocaine, 120%; nicotine+cocaine, 143%).
| Animal Model: | Male C57BL6/J mice (6- to 9-wk-old) |
| Dosage: | 20 μg/mL (Together with nicotine for 7 d, followed by the injection of cocaine) |
| Administration: | Oral administration; 7 days |
| Result: | Blocked nicotine and cocaine-induced facilitation of LTP. |
安全信息
| WGK Germany | 3 |
|---|
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-103430A | 8-BROMO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL HYDROBROMIDE SKF-83566 | 99295-33-7 | 5 mg | 950元 |
| 2026/06/05 | HY-103430A | 8-BROMO-2,3,4,5-TETRAHYDRO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL HYDROBROMIDE SKF-83566 | 99295-33-7 | 10 mM * 1 mL in DMSO | 1045元 |